Further vindication for Novartis in radioligand space

23 March 2021

Swiss pharma giant Novartis (NOVN: VX) has announced a positive result of its Phase III study with the radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer.

The VISION study is evaluating the efficacy and safety of 177Lu-PSMA-617 in progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard of care alone.

"We intend to submit these data to regulatory authorities as soon as possible"Both primary endpoints of overall survival and radiographic progression-free survival were met, helping to move closer the ambition of becoming the targeted treatment for at least 80% of patients with advanced prostate cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK